vs
ANI PHARMACEUTICALS INC（ANIP）与GIBRALTAR INDUSTRIES, INC.（ROCK）财务数据对比。点击上方公司名可切换其他公司
ANI PHARMACEUTICALS INC的季度营收约是GIBRALTAR INDUSTRIES, INC.的1.1倍（$247.1M vs $225.0M），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 24.9%），ANI PHARMACEUTICALS INC自由现金流更多（$29.1M vs $26.2M），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs -12.3%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
直布罗陀工业公司是专业建筑、基础设施及可再生能源产品制造商与分销商，主营通风系统、屋面配件、太阳能安装支架、园林景观产品等，主要服务北美地区住宅、商业建筑及清洁能源市场，专注提供创新可持续的客户解决方案。
ANIP vs ROCK — 直观对比
营收规模更大
ANIP
是对方的1.1倍
$225.0M
营收增速更快
ANIP
高出4.7%
24.9%
自由现金流更多
ANIP
多$2.9M
$26.2M
两年增速更快
ANIP
近两年复合增速
-12.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $225.0M |
| 净利润 | $27.5M | — |
| 毛利率 | — | 25.3% |
| 营业利润率 | 14.1% | 7.9% |
| 净利率 | 11.1% | — |
| 营收同比 | 29.6% | 24.9% |
| 净利润同比 | 367.5% | — |
| 每股收益（稀释后） | $1.14 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPROCK
| Q4 25 | $247.1M | $225.0M | ||
| Q3 25 | $227.8M | $310.9M | ||
| Q2 25 | $211.4M | $309.5M | ||
| Q1 25 | $197.1M | $290.0M | ||
| Q4 24 | $190.6M | $180.1M | ||
| Q3 24 | $148.3M | $277.1M | ||
| Q2 24 | $138.0M | $273.6M | ||
| Q1 24 | $137.4M | $292.5M |
净利润ANIPROCK
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | $-89.1M | ||
| Q2 25 | $8.5M | $26.0M | ||
| Q1 25 | $15.7M | $21.1M | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | $34.0M | ||
| Q2 24 | $-2.3M | $32.2M | ||
| Q1 24 | $18.2M | $24.9M |
毛利率ANIPROCK
| Q4 25 | — | 25.3% | ||
| Q3 25 | — | 26.6% | ||
| Q2 25 | — | 28.4% | ||
| Q1 25 | — | 26.8% | ||
| Q4 24 | — | 29.0% | ||
| Q3 24 | — | 29.4% | ||
| Q2 24 | — | 30.5% | ||
| Q1 24 | — | 28.9% |
营业利润率ANIPROCK
| Q4 25 | 14.1% | 7.9% | ||
| Q3 25 | 15.9% | 12.8% | ||
| Q2 25 | 6.6% | 12.8% | ||
| Q1 25 | 13.3% | 8.8% | ||
| Q4 24 | -2.3% | 13.3% | ||
| Q3 24 | -13.8% | 15.6% | ||
| Q2 24 | 3.7% | 14.9% | ||
| Q1 24 | 14.8% | 10.8% |
净利率ANIPROCK
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | -28.6% | ||
| Q2 25 | 4.0% | 8.4% | ||
| Q1 25 | 8.0% | 7.3% | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | 12.3% | ||
| Q2 24 | -1.7% | 11.8% | ||
| Q1 24 | 13.2% | 8.5% |
每股收益（稀释后）ANIPROCK
| Q4 25 | $1.14 | — | ||
| Q3 25 | $1.13 | $-2.98 | ||
| Q2 25 | $0.36 | $0.87 | ||
| Q1 25 | $0.69 | — | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $-1.27 | $1.11 | ||
| Q2 24 | $-0.14 | $1.05 | ||
| Q1 24 | $0.82 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $115.7M |
| 总债务越低越好 | — | $0 |
| 股东权益账面价值 | $540.7M | $950.4M |
| 总资产 | $1.4B | $1.4B |
| 负债/权益比越低杠杆越低 | — | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资ANIPROCK
| Q4 25 | $285.6M | $115.7M | ||
| Q3 25 | $262.6M | $89.4M | ||
| Q2 25 | $217.8M | $43.3M | ||
| Q1 25 | $149.8M | $25.1M | ||
| Q4 24 | $144.9M | $269.5M | ||
| Q3 24 | $145.0M | $228.9M | ||
| Q2 24 | $240.1M | $179.1M | ||
| Q1 24 | $228.6M | $146.7M |
总债务ANIPROCK
| Q4 25 | — | $0 | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $0 | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $0 |
股东权益ANIPROCK
| Q4 25 | $540.7M | $950.4M | ||
| Q3 25 | $505.8M | $951.8M | ||
| Q2 25 | $436.8M | $1.0B | ||
| Q1 25 | $418.6M | $1.0B | ||
| Q4 24 | $403.7M | $1.0B | ||
| Q3 24 | $405.9M | $1.0B | ||
| Q2 24 | $455.8M | $975.7M | ||
| Q1 24 | $452.0M | $940.2M |
总资产ANIPROCK
| Q4 25 | $1.4B | $1.4B | ||
| Q3 25 | $1.4B | $1.4B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.3B | $1.4B | ||
| Q4 24 | $1.3B | $1.4B | ||
| Q3 24 | $1.3B | $1.4B | ||
| Q2 24 | $920.8M | $1.4B | ||
| Q1 24 | $914.5M | $1.3B |
负债/权益比ANIPROCK
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $35.5M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $26.2M |
| 自由现金流率自由现金流/营收 | 11.8% | 11.7% |
| 资本支出强度资本支出/营收 | 0.5% | 4.1% |
| 现金转化率经营现金流/净利润 | 1.10× | — |
| 过去12个月自由现金流最近4个季度 | $171.4M | $120.6M |
8季度趋势，按日历期对齐
经营现金流ANIPROCK
| Q4 25 | $30.4M | $35.5M | ||
| Q3 25 | $44.1M | $73.0M | ||
| Q2 25 | $75.8M | $44.9M | ||
| Q1 25 | $35.0M | $13.7M | ||
| Q4 24 | $15.9M | $19.9M | ||
| Q3 24 | $12.5M | $64.7M | ||
| Q2 24 | $17.4M | $36.5M | ||
| Q1 24 | $18.3M | $53.2M |
自由现金流ANIPROCK
| Q4 25 | $29.1M | $26.2M | ||
| Q3 25 | $38.0M | $64.8M | ||
| Q2 25 | $71.8M | $27.3M | ||
| Q1 25 | $32.5M | $2.3M | ||
| Q4 24 | $13.5M | $14.1M | ||
| Q3 24 | $7.7M | $60.5M | ||
| Q2 24 | $13.0M | $33.5M | ||
| Q1 24 | $13.7M | $48.8M |
自由现金流率ANIPROCK
| Q4 25 | 11.8% | 11.7% | ||
| Q3 25 | 16.7% | 20.8% | ||
| Q2 25 | 34.0% | 8.8% | ||
| Q1 25 | 16.5% | 0.8% | ||
| Q4 24 | 7.1% | 7.8% | ||
| Q3 24 | 5.2% | 21.8% | ||
| Q2 24 | 9.4% | 12.2% | ||
| Q1 24 | 10.0% | 16.7% |
资本支出强度ANIPROCK
| Q4 25 | 0.5% | 4.1% | ||
| Q3 25 | 2.7% | 2.6% | ||
| Q2 25 | 1.9% | 5.7% | ||
| Q1 25 | 1.3% | 3.9% | ||
| Q4 24 | 1.3% | 3.3% | ||
| Q3 24 | 3.2% | 1.5% | ||
| Q2 24 | 3.2% | 1.1% | ||
| Q1 24 | 3.3% | 1.5% |
现金转化率ANIPROCK
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | 1.73× | ||
| Q1 25 | 2.23× | 0.65× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.13× | ||
| Q1 24 | 1.00× | 2.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
ROCK
| Transferred At Point In Time | $183.5M | 82% |
| Infrastructure | $22.5M | 10% |
| Other | $18.9M | 8% |
